MPS Disorders Explained: Biospecimen Needs for Mucopolysaccharidosis Research

Photo Credit: CDC/ Dr. Mae Melvin

Mucopolysaccharidosis (MPS) disorders represent a family of rare genetic diseases caused by deficiencies in specific lysosomal enzymes needed to break down glycosaminoglycans (GAGs), and are among the conditions supported by our genetic disease biospecimen portfolio. These inherited metabolic disorders affect approximately 1 in 25,000 births and encompass seven distinct disease types, each caused by deficiency of a different enzyme. From MPS I (Hurler syndrome) to MPS VII, these conditions share common features of GAG accumulation leading to progressive multi-system dysfunction.

Research into MPS disorders has accelerated in recent years, driven by the development of enzyme replacement therapies, gene therapies, and substrate reduction approaches. Each of these therapeutic strategies requires specialized biospecimens for development, validation, and monitoring. Understanding the unique biospecimen needs for MPS research is essential for investigators working to advance treatments for these devastating conditions.

For MPS researchers, biospecimens serve multiple critical functions: confirming genetic diagnosis, measuring enzyme activity, quantifying GAG accumulation, monitoring treatment response, and understanding disease natural history. The quality and characterization of these samples can significantly impact research outcomes and the development of more effective therapies.

Understanding MPS Disorder Types and Genetic Basis

The MPS disorders are classified into seven types (MPS I, II, III, IV, VI, VII, and IX), each caused by deficiency of a specific lysosomal enzyme. MPS I results from deficiency of alpha-L-iduronidase and ranges from severe (Hurler syndrome) to attenuated (Scheie syndrome) forms. MPS II (Hunter syndrome) is the only X-linked MPS disorder, caused by iduronate-2-sulfatase deficiency.

MPS III (Sanfilippo syndrome) has four subtypes (A, B, C, D), each caused by deficiency of different enzymes involved in heparan sulfate degradation. This group is characterized by severe central nervous system involvement and progressive neurodegeneration. MPS IV (Morquio syndrome) affects primarily the skeleton, while MPS VI (Maroteaux-Lamy syndrome) causes severe skeletal and visceral manifestations without cognitive impairment.

Each MPS type accumulates specific GAGs in different tissues, creating distinct clinical phenotypes. This variability means biospecimen requirements differ depending on the MPS type being studied. Cellular immune samples such as PBMCs, purified T cells, and NK cells are commonly used to investigate genotype-phenotype relationships and immune involvement in disease progression.

Essential Biospecimen Types for MPS Research

Blood samples form the foundation of MPS biospecimen collections. Whole blood enables DNA extraction for genetic testing and variant characterization. Plasma provides material for enzyme activity assays critical for confirming diagnosis and monitoring therapy, while serum supports GAG quantification as a primary disease biomarker.

Urine specimens are uniquely valuable because GAGs are excreted at elevated levels. Serial collections allow researchers to track substrate accumulation over time, particularly in pediatric studies.

Fibroblast cell lines derived from skin punch biopsy samples provide essential cellular models for studying disease mechanisms, validating gene therapies, and testing pharmacologic approaches.

For inflammatory or joint-related manifestations, extracellular matrices such as synovial fluid can offer additional insight into disease burden and treatment response.

GAG Quantification and Analysis

Glycosaminoglycan quantification is a cornerstone of MPS research. Measurements in serum, plasma, and tissue-derived samples correlate with disease severity and therapeutic response.

Advanced analytical techniques including mass spectrometry now enable highly sensitive GAG measurements even in small sample volumes. Larger-volume validation studies may utilize bulk plasma to establish reference ranges and assay performance across populations.

Enzyme Activity Testing Requirements

Enzyme activity assays confirm the biochemical defect underlying each MPS type. These tests commonly rely on plasma, isolated leukocytes from whole blood, or high-yield collections such as leukopak and GMP leukopak preparations for expanded cell-based testing.

Longitudinal enzyme measurements in treated patients help demonstrate target engagement and optimize dosing regimens.

Genetic Characterization and Annotation

Comprehensive genetic characterization links biospecimens to pathogenic variants, mutation type, and predicted enzyme impact. RNA analysis from patient-derived cells reveals aberrant splicing patterns and reduced transcript levels that explain disease severity.

Diverse genomic datasets generated from immune cells such as PBMCs improve variant interpretation accuracy and enable genotype-phenotype correlation studies.

Clinical Annotation for MPS Biospecimens

MPS biospecimens require detailed clinical annotation capturing the multi-system nature of disease. Growth measurements, cardiac function, skeletal imaging, and neurocognitive testing should be linked to biospecimen collection time points.

Treatment history is critical since many patients receive enzyme replacement therapy or substrate reduction therapy. Accurate annotation ensures biomarker analysis correctly accounts for therapeutic effects.

Longitudinal Collections for Natural History Studies

Natural history studies benefit enormously from longitudinal collections tracking biomarker progression over time. Serial plasma, serum, and cellular samples reveal disease trajectory and treatment response.

Pediatric longitudinal collections are particularly valuable, capturing disease progression during development and organ maturation.

Sourcing MPS Biospecimens for Research

Researchers may access MPS biospecimens through advocacy organizations, academic centers, or specialized biospecimen providers. Collections spanning multiple sample types — including immune cell isolates, apheresis leukopaks, and biofluids — help accelerate research programs while ensuring quality and compliance.

Conclusion

MPS disorders present unique challenges and opportunities for biospecimen-based research. The need for specialized analyses including GAG quantification and enzyme testing, combined with disease rarity, makes access to well-characterized samples particularly valuable.

As gene therapies and novel enzyme formulations advance, demand for high-quality biospecimens will continue to grow. Establishing reliable access to diverse sample types early in research planning can significantly accelerate MPS research programs and ultimately benefit patients affected by these devastating disorders. Explore our full genetic disease biospecimen portfolio for related rare and inherited metabolic conditions.